DE69332583T2 - Maspin- ein neues serpin mit tumor unterdrückender aktivität - Google Patents

Maspin- ein neues serpin mit tumor unterdrückender aktivität

Info

Publication number
DE69332583T2
DE69332583T2 DE69332583T DE69332583T DE69332583T2 DE 69332583 T2 DE69332583 T2 DE 69332583T2 DE 69332583 T DE69332583 T DE 69332583T DE 69332583 T DE69332583 T DE 69332583T DE 69332583 T2 DE69332583 T2 DE 69332583T2
Authority
DE
Germany
Prior art keywords
maspin
repressive activity
tumor
serpin
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69332583T
Other languages
English (en)
Other versions
DE69332583D1 (de
Inventor
Ruth Sager
Zhiqiang Zou
Anthony Anisowicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of DE69332583D1 publication Critical patent/DE69332583D1/de
Publication of DE69332583T2 publication Critical patent/DE69332583T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69332583T 1992-09-01 1993-09-01 Maspin- ein neues serpin mit tumor unterdrückender aktivität Expired - Fee Related DE69332583T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93882392A 1992-09-01 1992-09-01
PCT/US1993/008322 WO1994005804A1 (en) 1992-09-01 1993-09-01 Maspin, a novel serpin with tumor suppressing activity

Publications (2)

Publication Number Publication Date
DE69332583D1 DE69332583D1 (de) 2003-01-30
DE69332583T2 true DE69332583T2 (de) 2003-11-20

Family

ID=25472030

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332583T Expired - Fee Related DE69332583T2 (de) 1992-09-01 1993-09-01 Maspin- ein neues serpin mit tumor unterdrückender aktivität

Country Status (6)

Country Link
EP (1) EP0662150B1 (de)
JP (1) JP3489629B2 (de)
AT (1) ATE229983T1 (de)
CA (1) CA2143188A1 (de)
DE (1) DE69332583T2 (de)
WO (1) WO1994005804A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
JP2002085093A (ja) * 2000-09-08 2002-03-26 Kuo Kwang Biotech Corp 扁平上皮細胞癌患者の生存予測
WO2007095583A2 (en) * 2006-02-14 2007-08-23 Children's Memorial Research Center Methods for treating cancer and sensitizing cancer cells using the serine protease inhibitor, maspin
CA3031232A1 (en) * 2016-07-20 2018-01-25 The Lubrizol Corporation Alkyl phosphate amine salts for use in lubricants
EP3903805A4 (de) * 2018-12-28 2022-09-14 Neogentc Corp. (Convergence Innovation Building, Asan Institute for Life Sciences, Pungnap-dong) Immunpotenzierende oder antikrebsaktivitätssteigernde zusammensetzung mit einer mal-exprimierten stammzellenähnlichen gedächtnis-t-zelle als wirkstoff

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888278A (en) * 1985-10-22 1989-12-19 University Of Massachusetts Medical Center In-situ hybridization to detect nucleic acid sequences in morphologically intact cells
EP0631584A4 (de) * 1991-02-28 1998-07-01 Dana Farber Cancer Inst Inc Krebs diagnose und therapie.

Also Published As

Publication number Publication date
EP0662150A4 (de) 1997-01-29
EP0662150B1 (de) 2002-12-18
JPH08500977A (ja) 1996-02-06
ATE229983T1 (de) 2003-01-15
DE69332583D1 (de) 2003-01-30
EP0662150A1 (de) 1995-07-12
WO1994005804A1 (en) 1994-03-17
CA2143188A1 (en) 1994-03-17
JP3489629B2 (ja) 2004-01-26

Similar Documents

Publication Publication Date Title
NO913211L (no) Nytt monoklonalt antistoff mot nytt antigen knyttet til menneske-tumorer.
BG60256B1 (bg) Рекомбинантен метод за получаване на лимфотоксин
ES2073571T3 (es) Aplicacion de nuevos fragmentos de adn como secuencia que codifica un peptido señal para la secrecion de proteinas maduras, mediante levaduras recombinantes, cassettes de expresion, levaduras transformadas y procedimiento correspondiente de preparacion de proteinas.
ES2009590A6 (es) Metodo de preparacion de proteina de cadena pesada del factor tisular humano.
CA2108473A1 (en) Heregulins (hrgs) binding proteins of p185erb2
NO20074516L (no) Pattedyrcytokinlignende polypeptid-1
DE69333802D1 (de) Äusseres membranprotein von haemophilus
HK1008021A1 (en) Growth hormone receptor
ZA943464B (en) Vascular endothelial growth factor 2
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
DE69434926D1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
NZ502391A (en) Mammalian cytokine: interleukin-B30 and related reagents
ATE132197T1 (de) Monoklonale antikörper
Shirakawa et al. Production of bone-resorbing activity corresponding to interleukin-1α by adult T-cell leukemia cells in humans
ES8704207A1 (es) Procedimiento para preparar una molecula de adn
DE69332583D1 (de) Maspin- ein neues serpin mit tumor unterdrückender aktivität
NO983238L (no) Exodus kjemokin materialer og fremgangsmÕter
DK193187D0 (da) Interferoninduceret humanprotein paa ren form, dets fremstilling og anvendlese
Yasuda et al. Partial purification and characterization of feline gamma-like interferon
Roman Jr et al. Studies on the Molecular Basis for C1̄s Action and Comparison of C1̄s with Other Tryptic Proteases
Hopper et al. Structural evidence for an unblocked VHI sub-subgroup of human heavy chains
JPS6410998A (en) Tumor cell inhibitory factor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee